Opthea Ltd
ASX:OPT
Opthea Ltd
Research & Development
Opthea Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Opthea Ltd
ASX:OPT
|
Research & Development
-$126.8m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
-37%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Research & Development
-$34.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
CSL Ltd
ASX:CSL
|
Research & Development
-$1.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-11%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Research & Development
-AU$7.4m
|
CAGR 3-Years
-82%
|
CAGR 5-Years
-85%
|
CAGR 10-Years
-14%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Research & Development
-AU$126.2m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Research & Development
-AU$70.1m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
-38%
|
|
Opthea Ltd
Glance View
Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing and commercializing therapies primarily for eye diseases. The firm's lead product candidate OPT-302, is a soluble form of vascular endothelial growth factors-3 (VEGFR 3) in clinical development as a therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The firm's technology platform focuses on vascular endothelial growth factors, such as VEGF C, VEGF D and VEGF Receptor 3 for the treatment of diseases associated with blood and lymphatic vessel growth (angiogenesis and lymphangiogenesis), as well as vascular leakage. The company has also conducted various activities to support its clinical development programs in wet AMD and DME, including clinical data analysis and manufacturing of OPT-302 for use in Phase III clinical trials.
See Also
What is Opthea Ltd's Research & Development?
Research & Development
-126.8m
USD
Based on the financial report for Jun 30, 2025, Opthea Ltd's Research & Development amounts to -126.8m USD.
What is Opthea Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-37%
Over the last year, the Research & Development growth was 28%. The average annual Research & Development growth rates for Opthea Ltd have been -17% over the past three years , -60% over the past five years , and -37% over the past ten years .
